Which has higher earnings & valuation, CGON or IMCR?

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,637.21 -$160.99M -$2.69 N/A Immunocore $400.02M 4.12 -$35.51M -$0.37 N/A

Does the media favor CGON or IMCR?

In the previous week, CG Oncology had 3 more articles in the media than Immunocore. MarketBeat recorded 7 mentions for CG Oncology and 4 mentions for Immunocore. CG Oncology's average media sentiment score of 0.82 beat Immunocore's score of 0.47 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MIRM or IMCR?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Immunocore. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 4 mentions for Immunocore. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat Immunocore's score of 0.47 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ORKA or IMCR?

In the previous week, Oruka Therapeutics had 11 more articles in the media than Immunocore. MarketBeat recorded 15 mentions for Oruka Therapeutics and 4 mentions for Immunocore. Immunocore's average media sentiment score of 0.47 beat Oruka Therapeutics' score of 0.26 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IMCR or TVTX?

In the previous week, Travere Therapeutics had 33 more articles in the media than Immunocore. MarketBeat recorded 37 mentions for Travere Therapeutics and 4 mentions for Immunocore. Immunocore's average media sentiment score of 0.47 beat Travere Therapeutics' score of 0.25 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 16 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Immunocore (IMCR) Competitors

$32.00 -0.30 (-0.93%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$31.83 -0.17 (-0.53%)

As of 09/18/2026 07:30 PM Eastern

Compare

IMCR vs. CGON, MIRM, ORKA, KNSA, and TVTX

Should you buy Immunocore stock or one of its competitors? Immunocore's main competitors and comparable companies include CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Oruka Therapeutics (ORKA), Kiniksa Pharmaceuticals International (KNSA), and Travere Therapeutics (TVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunocore compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Immunocore has a net margin of -4.20% compared to CG Oncology's net margin of -3,602.68%. Immunocore's return on equity of -4.54% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Immunocore	-4.20%	-4.54%	-1.66%

CG Oncology has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

In the previous week, CG Oncology had 3 more articles in the media than Immunocore. MarketBeat recorded 7 mentions for CG Oncology and 4 mentions for Immunocore. CG Oncology's average media sentiment score of 0.82 beat Immunocore's score of 0.47 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CG Oncology presently has a consensus target price of $87.78, suggesting a potential upside of 17.63%. Immunocore has a consensus target price of $56.38, suggesting a potential upside of 76.17%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

Immunocore has higher revenue and earnings than CG Oncology. Immunocore is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,637.21	-$160.99M	-$2.69	N/A
Immunocore	$400.02M	4.12	-$35.51M	-$0.37	N/A

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 10.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Immunocore beats CG Oncology on 11 of the 17 factors compared between the two stocks.

How does Immunocore compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Mirum Pharmaceuticals has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A
Immunocore	$400.02M	4.12	-$35.51M	-$0.37	N/A

Mirum Pharmaceuticals presently has a consensus price target of $137.31, suggesting a potential upside of 49.53%. Immunocore has a consensus price target of $56.38, suggesting a potential upside of 76.17%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

Immunocore has a net margin of -4.20% compared to Mirum Pharmaceuticals' net margin of -139.18%. Immunocore's return on equity of -4.54% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Immunocore	-4.20%	-4.54%	-1.66%

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Immunocore. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 4 mentions for Immunocore. Mirum Pharmaceuticals' average media sentiment score of 0.62 beat Immunocore's score of 0.47 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunocore	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.5% of Immunocore shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 10.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Mirum Pharmaceuticals and Immunocore tied by winning 8 of the 16 factors compared between the two stocks.

How does Immunocore compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Oruka Therapeutics currently has a consensus price target of $133.00, indicating a potential upside of 40.06%. Immunocore has a consensus price target of $56.38, indicating a potential upside of 76.17%. Given Immunocore's higher probable upside, analysts plainly believe Immunocore is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

Oruka Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -4.20%. Immunocore's return on equity of -4.54% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Immunocore	-4.20%	-4.54%	-1.66%

In the previous week, Oruka Therapeutics had 11 more articles in the media than Immunocore. MarketBeat recorded 15 mentions for Oruka Therapeutics and 4 mentions for Immunocore. Immunocore's average media sentiment score of 0.47 beat Oruka Therapeutics' score of 0.26 indicating that Immunocore is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunocore	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore has higher revenue and earnings than Oruka Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Immunocore	$400.02M	4.12	-$35.51M	-$0.37	N/A

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Oruka Therapeutics has a beta of -0.34, suggesting that its stock price is 134% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

Immunocore beats Oruka Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Immunocore compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Immunocore (NASDAQ:IMCR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Immunocore's net margin of -4.20%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Immunocore	-4.20%	-4.54%	-1.66%

In the previous week, Immunocore had 4 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 4 mentions for Immunocore and 0 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.06 beat Immunocore's score of 0.47 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Overall Sentiment
Kiniksa Pharmaceuticals International	Positive
Immunocore	Neutral

Kiniksa Pharmaceuticals International presently has a consensus target price of $87.38, indicating a potential upside of 13.23%. Immunocore has a consensus target price of $56.38, indicating a potential upside of 76.17%. Given Immunocore's higher probable upside, analysts plainly believe Immunocore is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58

Kiniksa Pharmaceuticals International has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	8.89	$59.01M	$0.97	79.56
Immunocore	$400.02M	4.12	-$35.51M	-$0.37	N/A

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 10.1% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Kiniksa Pharmaceuticals International beats Immunocore on 12 of the 17 factors compared between the two stocks.

How does Immunocore compare to Travere Therapeutics?

Immunocore (NASDAQ:IMCR) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Immunocore presently has a consensus target price of $56.38, suggesting a potential upside of 76.17%. Travere Therapeutics has a consensus target price of $68.00, suggesting a potential upside of 8.35%. Given Immunocore's higher possible upside, research analysts clearly believe Immunocore is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.58
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Immunocore has a net margin of -4.20% compared to Travere Therapeutics' net margin of -7.35%. Immunocore's return on equity of -4.54% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-4.20%	-4.54%	-1.66%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

In the previous week, Travere Therapeutics had 33 more articles in the media than Immunocore. MarketBeat recorded 37 mentions for Travere Therapeutics and 4 mentions for Immunocore. Immunocore's average media sentiment score of 0.47 beat Travere Therapeutics' score of 0.25 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	16 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.5% of Immunocore shares are owned by institutional investors. 10.1% of Immunocore shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Travere Therapeutics has higher revenue and earnings than Immunocore. Travere Therapeutics is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.12	-$35.51M	-$0.37	N/A
Travere Therapeutics	$490.73M	12.06	-$25.55M	-$0.46	N/A

Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Summary

Immunocore beats Travere Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Immunocore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMCR vs. The Competition

Export

Metric	Immunocore	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.66B	$3.92B	$7.25B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-86.48	14.30	275.79	25.40
Price / Sales	4.12	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	4.26	15.45	10.46	6.33
Net Income	-$35.51M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-1.84%	-1.21%	0.59%	1.12%
1 Month Performance	-13.19%	-4.42%	-2.01%	-2.67%
1 Year Performance	-1.84%	37.81%	18.09%	6.01%

Immunocore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMCR Immunocore	3.5879 of 5 stars	$32.00 -0.9%	$56.38 +76.2%	-4.2%	$1.66B	$400.02M	N/A	524
CGON CG Oncology	2.852 of 5 stars	$72.89 -1.2%	$87.78 +20.4%	+92.2%	$6.46B	$6.23M	N/A	142
MIRM Mirum Pharmaceuticals	3.0443 of 5 stars	$94.45 -2.4%	$137.31 +45.4%	+21.9%	$6.16B	$618.07M	N/A	433	Gap Up
ORKA Oruka Therapeutics	3.4418 of 5 stars	$91.33 -4.8%	$133.00 +45.6%	+472.7%	$6.05B	N/A	N/A	68	Insider Trade
KNSA Kiniksa Pharmaceuticals International	3.9766 of 5 stars	$75.02 -2.0%	$87.38 +16.5%	+114.8%	$5.87B	$840.85M	77.58	366	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMCR) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunocore (IMCR) Competitors

IMCR vs. CGON, MIRM, ORKA, KNSA, and TVTX

How does Immunocore compare to CG Oncology?

Summary

How does Immunocore compare to Mirum Pharmaceuticals?

Summary

How does Immunocore compare to Oruka Therapeutics?

Summary

How does Immunocore compare to Kiniksa Pharmaceuticals International?

Summary

How does Immunocore compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunocore (IMCR) Competitors

IMCR vs. CGON, MIRM, ORKA, KNSA, and TVTX

How does Immunocore compare to CG Oncology?

Is CGON or IMCR more profitable?

Which has more volatility & risk, CGON or IMCR?

Does the media favor CGON or IMCR?

Do analysts rate CGON or IMCR?

Which has higher earnings & valuation, CGON or IMCR?

Do insiders and institutionals hold more shares of CGON or IMCR?

Summary

How does Immunocore compare to Mirum Pharmaceuticals?

Which has more risk & volatility, MIRM or IMCR?

Which has preferable valuation and earnings, MIRM or IMCR?

Do analysts recommend MIRM or IMCR?

Is MIRM or IMCR more profitable?

Does the media favor MIRM or IMCR?

Do institutionals & insiders hold more shares of MIRM or IMCR?

Summary

How does Immunocore compare to Oruka Therapeutics?

Do analysts rate ORKA or IMCR?

Is ORKA or IMCR more profitable?

Does the media prefer ORKA or IMCR?

Which has preferable earnings and valuation, ORKA or IMCR?

Do institutionals and insiders have more ownership in ORKA or IMCR?

Which has more risk & volatility, ORKA or IMCR?

Summary

How does Immunocore compare to Kiniksa Pharmaceuticals International?

Is KNSA or IMCR more profitable?

Does the media favor KNSA or IMCR?

Do analysts rate KNSA or IMCR?

Which has more volatility & risk, KNSA or IMCR?

Which has stronger valuation and earnings, KNSA or IMCR?

Do institutionals & insiders have more ownership in KNSA or IMCR?

Summary

How does Immunocore compare to Travere Therapeutics?

Do analysts rate IMCR or TVTX?

Is IMCR or TVTX more profitable?

Does the media refer more to IMCR or TVTX?

Do insiders & institutionals hold more shares of IMCR or TVTX?

Which has preferable valuation & earnings, IMCR or TVTX?

Which has more risk and volatility, IMCR or TVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR vs. The Competition

Immunocore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools